Telix's Glioblastoma Drug TLX101-Tx Completes Phase 1 Enrollment with No Dose-Limiting Toxicities
TLX sits 64% above its 52-week low of $6.28 on light trading volume (0.3× avg).
Summary
Telix Pharmaceuticals announced the completion of patient enrolment and confirmed dosing in its Phase 1 IPAX-2 study for TLX101-Tx in first-line glioblastoma. Crucially, the study observed no dose-limiting toxicities (DLTs) even at the maximum administered dose, which is a significant positive safety signal for the drug candidate. This de-risks the early development of TLX101-Tx, which is also currently being evaluated in the pivotal (Phase 3) IPAX BrIGHT trial for recurrent glioblastoma. The positive safety profile supports the continued development of this targeted radiopharmaceutical for a highly aggressive cancer with substantial unmet medical need. Investors will now monitor the progress of the ongoing pivotal trial and future updates on the IPAX-2 study's primary endpoint confirmation.
At the time of this announcement, TLX was trading at $10.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $6.28 to $18.49. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.